跳至主要内容
临床试验/JPRN-UMIN000004410
JPRN-UMIN000004410已完成3 期

Randomized phase III study of adjuvant chemotherapy with combination therapy of gemcitabine and S-1 vs. gemcitabine alone in patients with resected pancreatic cancer (JSAP-04) - Phase III study of gemcitabine and S-1 combination therapy for resected pancreatic cancer

Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer (JSAP)0 个研究点目标入组 300 人开始时间: 2010年10月20日最近更新:
适应症

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
300

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 79years-old(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1) History of serious complications related to surgery 2) Patients under treatment with phenytoin, warfarin potassium or flucytosine. 3) Uncontrolled watery diarrhea 4) Sever mental disorder 5) Active infection 6) Serious complications 7) Pulmonary fibrosis or interstitial pneumonia 8) Clinically significant pleural effusions or ascites 9) Active double cancer (synchronous double cancer or asynchronous double cancer with disease-free duration of 2 years or less) 10) History of chemotherapy or radiotherapy for other malignant disease within one year 11) Unable to receive contrast enhanced CT nor MRI due to allergic reaction to contrast medium 12) Pregnant females, possibly pregnant females, females wishing to become pregnant, and males that are currently attempting to produce a pregnancy 13) Inadequate physical condition, as diagnosed by primary physician

研究者

发起方
Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer (JSAP)

相似试验

Randomized phase III study of adjuvant chemotherapy... | 临床试验